Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NSC23925 is a selective and effective inhibitor of P-glycoprotein (Pgp).
Description | NSC23925 is a selective and effective inhibitor of P-glycoprotein (Pgp). |
In vitro | NSC23925 specifically inhibits Pgp overexpression to prevent the emergence of paclitaxel resistance during paclitaxel treatment. NSC23925 reverses chemoresistance in a wide variety of tumor types where Multidrug resistance 1 (MDR1) is highly expressed. SKOV-3 cells with long-term exposure of 1 μM NSC23925 display stable growth in the culture medium. However, the mean concentration of NSC23925 required for maximal reversal of resistance in SKOV-3TR or OVCAR8TR to cytotoxic drugs is 0.5 μM to 1 μM. The IC50 for NSC23925 is 8 μM in SKOV-3/SKOV-3TR and 25 μM in OVCAR8/OVCAR8TR cell lines. Maximal reversal of MDR is typically seen in NSC23925 doses between 0.5 and 1 μM [1][2]. |
In vivo | The usage of NSC23925 significantly prolongs the anticancer efficacy of paclitaxel in paclitaxel chemotherapy. Both saline alone and NSC23925 alone treated tumors grow progressively [1]. |
Molecular Weight | 421.36 |
Formula | C22H26Cl2N2O2 |
CAS No. | 858474-14-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NSC23925 858474-14-3 Immunology/Inflammation Nrf2 NSC-23925 NSC 23925 inhibitor inhibit